Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.53 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.51 |
| ▸ | TOP2A | P11388 | 2/20 | 0.50 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8139161 | 1.00 | GSK3B (0.53) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL5620413 | 1.00 | GSK3B (0.53) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL5619172 | 1.00 | GSK3B (0.53) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL9096957 | 0.90 | STAT3 (0.56) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL8131449 | 0.90 | STAT3 (0.56) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL8131981 | 0.90 | STAT3 (0.56) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL501142 | 0.89 | GSK3B (0.50) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL14572392 | 0.89 | GSK3B (0.53) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL5236368 | 0.89 | GSK3B (0.50) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL4747724 | 0.87 | GSK3B (0.50) | GSK3BCACNA1FPOLBMAPK1CACNA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1304329-B1 | Pyridonecarboxylic acid derivatives and their use as antibacterial agents | DAIICHI SANKYO CO LTD (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1304329-B1 | Pyridonecarboxylic acid derivatives and their use as antibacterial agents | DAIICHI SANKYO CO LTD (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7186843-B2 | potent antibacterial activity against various bacteria including drug-resistant strains | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
| EP-1134219-B1 | CYCLOALKYL-SUBSTITUTED AMINOMETHYLPYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | DAIICHI PHARMACEUTICAL CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| US-6762181-B1 | BROAD ANTIBACTERIAL ACTIVITY INCLUDING DRUG RESISTANT STAPHYLOCOCCUS AUREUS (MRSA), PNEUMOCOCCUS (PRSP) AND ENTEROCOCCUS (VRE); SAFELY USED IN CONJUCTION WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-13 | — | — | US | disclosed |
| EP-1182202-B1 | AMINOMETHYLPYRROLIDINE DERIVATIVES HAVING AROMATIC SUBSTITUENTS | DAIICHI SEIYAKU CO (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-6573260-B1 | Antibiotics | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-0816355-B1 | HETEROCYCLIC SPIRO DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-0807630-B1 | HETEROCYCLIC COMPOUNDS | DAIICHI SEIYAKU CO (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-5703094-A | Quinolone- and naphthyridonecarboxylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-30 | — | — | US | disclosed |
| EP-0721948-B1 | Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents | BAYER AG (DE) | 1997-12-03 | — | — | EP | disclosed |
| EP-0807630-A1 | HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
| US-5679689-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-10-21 | — | — | US | disclosed |
| US-5605910-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-02-25 | — | — | US | disclosed |
| US-5545642-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-08-13 | — | — | US | disclosed |
| EP-0721948-A1 | Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents | BAYER AG (DE) | 1996-07-17 | — | — | EP | disclosed |
| EP-0705828-A1 | Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents | BAYER AG (DE) | 1996-04-10 | — | — | EP | disclosed |
| EP-0704443-A2 | Quinolone and naphthyridone carboxylic acid derivatives | BAYER AG (DE) | 1996-04-03 | — | — | EP | disclosed |
| WO-1996001262-A1 | NOVEL QUINOLINE COMPOUND AND PROCESS FOR PREPARATION THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 1996-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | Q6ZSR9, NAT1, NAT10 | GSK3B 4658/4885CACNA1F 1627/4885POLB 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.